Coral Laboratories [CORALAB] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
Coral Laboratories
BSE
Loading...
Sun Pharmaceutical
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Coral Laboratories wins in 8 metrics, Sun Pharmaceutical wins in 12 metrics, with 0 ties. Sun Pharmaceutical appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Coral Laboratories | Sun Pharmaceutical | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 10.41 | 37.73 | Coral Laboratories |
| Price-to-Book Ratio | 0.93 | 5.42 | Coral Laboratories |
| Debt-to-Equity Ratio | 1.77 | 3.26 | Coral Laboratories |
| PEG Ratio | -0.15 | -1.94 | Sun Pharmaceutical |
| EV/EBITDA | 4.64 | 23.98 | Coral Laboratories |
| Profit Margin (TTM) | 17.54% | 19.29% | Sun Pharmaceutical |
| Operating Margin (TTM) | 9.19% | 24.34% | Sun Pharmaceutical |
| EBITDA Margin (TTM) | 9.19% | 24.34% | Sun Pharmaceutical |
| Return on Equity | 12.01% | 15.08% | Sun Pharmaceutical |
| Return on Assets (TTM) | 10.53% | 11.87% | Sun Pharmaceutical |
| Free Cash Flow (TTM) | $-41.67M | $119.44B | Sun Pharmaceutical |
| Dividend Yield | 0.29% | 1.26% | Sun Pharmaceutical |
| 1-Year Return | -41.03% | -13.00% | Sun Pharmaceutical |
| Price-to-Sales Ratio (TTM) | 1.83 | 7.28 | Coral Laboratories |
| Enterprise Value | $823.11M | $3,678.87B | Sun Pharmaceutical |
| EV/Revenue Ratio | 0.81 | 6.84 | Coral Laboratories |
| Gross Profit Margin (TTM) | 53.58% | 79.58% | Sun Pharmaceutical |
| Revenue per Share (TTM) | $286 | $224 | Coral Laboratories |
| Earnings per Share (Diluted) | $50.14 | $43.23 | Coral Laboratories |
| Beta (Stock Volatility) | 0.70 | 0.28 | Sun Pharmaceutical |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Coral Laboratories vs Sun Pharmaceutical Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Coral Laboratories | -0.90% | 3.35% | 2.66% | -12.43% | -19.72% | -36.61% |
| Sun Pharmaceutical | 1.44% | 4.12% | 4.66% | -1.50% | -0.70% | -12.45% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Coral Laboratories | -41.03% | 95.66% | 39.82% | 8.95% | 318.43% | 440.61% |
| Sun Pharmaceutical | -13.00% | 69.49% | 239.84% | 85.82% | 711.29% | 2,598.03% |
News Based Sentiment: Coral Laboratories vs Sun Pharmaceutical
Coral Laboratories
News based Sentiment: MIXED
Coral Laboratories experienced a share price increase in October, but longer-term trends remain negative. The board's actions regarding cost audits and leadership appointments suggest a focus on stability and compliance, creating a mixed investment narrative.
Sun Pharmaceutical
News based Sentiment: MIXED
October was a month of significant contrasts for Sun Pharma. While the company demonstrated revenue growth and made strategic acquisitions, the imposition of a 100% US tariff on Indian pharmaceuticals presents a major headwind. This combination of positive and negative developments creates a mixed investment outlook.
Performance & Financial Health Analysis: Coral Laboratories vs Sun Pharmaceutical
| Metric | CORALAB | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.98B | ₹4.01T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 622 | 3,168,435 |
| 90 Day Avg. Volume | 887 | 2,778,768 |
| Last Close | ₹516.55 | ₹1,654.70 |
| 52 Week Range | ₹442.55 - ₹859.00 | ₹1,548.00 - ₹1,947.00 |
| % from 52W High | -39.87% | -15.01% |
| All-Time High | ₹1,190.00 (Jul 24, 2017) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -56.59% | -15.59% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.41% | 0.10% |
| Quarterly Earnings Growth | -0.71% | -0.20% |
| Financial Health | ||
| Profit Margin (TTM) | 0.18% | 0.19% |
| Operating Margin (TTM) | 0.09% | 0.24% |
| Return on Equity (TTM) | 0.12% | 0.15% |
| Debt to Equity (MRQ) | 1.77 | 3.26 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹562.96 | ₹300.99 |
| Cash per Share (MRQ) | ₹300.75 | ₹108.88 |
| Operating Cash Flow (TTM) | ₹106.44M | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹241.56M | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.29% | 1.26% |
| Last 12-Month Dividend | ₹1.50 | ₹21.00 |
Valuation & Enterprise Metrics Analysis: Coral Laboratories vs Sun Pharmaceutical
| Metric | CORALAB | SUNPHARMA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 10.41 | 37.73 |
| Forward P/E | 8.98 | 49.91 |
| PEG Ratio | -0.15 | -1.94 |
| Price to Sales (TTM) | 1.83 | 7.28 |
| Price to Book (MRQ) | 0.93 | 5.42 |
| Market Capitalization | ||
| Market Capitalization | ₹1.98B | ₹4.01T |
| Enterprise Value | ₹823.11M | ₹3.68T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.81 | 6.84 |
| Enterprise to EBITDA | 4.64 | 23.98 |
| Risk & Other Metrics | ||
| Beta | 0.70 | 0.28 |
| Book Value per Share (MRQ) | ₹562.96 | ₹300.99 |
Financial Statements Comparison: Coral Laboratories vs Sun Pharmaceutical
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CORALAB | SUNPHARMA |
|---|---|---|
| Revenue/Sales | ₹188.21M | ₹137.86B |
| Cost of Goods Sold | ₹87.37M | ₹28.15B |
| Gross Profit | ₹100.84M | ₹109.71B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹17.29M | ₹33.72B |
| EBITDA | ₹42.30M | ₹47.66B |
| Pre-Tax Income | ₹37.19M | ₹31.73B |
| Income Tax | ₹11.55M | ₹8.70B |
| Net Income (Profit) | ₹25.64M | ₹22.93B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CORALAB | SUNPHARMA |
|---|---|---|
| Cash & Equivalents | ₹34.06M | ₹102.69B |
| Total Current Assets | ₹1.77B | ₹526.24B |
| Total Current Liabilities | ₹249.58M | ₹181.94B |
| Long-Term Debt | ₹0 | ₹3.58B |
| Total Shareholders Equity | ₹2.01B | ₹724.86B |
| Retained Earnings | ₹1.71B | ₹578.62B |
| Property, Plant & Equipment | ₹217.44M | ₹100.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CORALAB | SUNPHARMA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CORALAB | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 622 | 3,168,435 |
| Average Daily Volume (90 Day) | 887 | 2,778,768 |
| Shares Outstanding | 3.57M | 2.40B |
| Float Shares | 803,040 | 1.06B |
| % Held by Insiders | 0.79% | 0.56% |
| % Held by Institutions | 0.00% | 0.25% |
Dividend Analysis & Yield Comparison: Coral Laboratories vs Sun Pharmaceutical
| Metric | CORALAB | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | ₹1.50 | ₹21.00 |
| Last 12-Month Dividend Yield | 0.29% | 1.26% |
| 3-Year Avg Annual Dividend | ₹1.17 | ₹14.67 |
| 3-Year Avg Dividend Yield | 0.26% | 0.46% |
| 3-Year Total Dividends | ₹3.50 | ₹44.00 |
| Ex-Dividend Date | Sep 19, 2025 | Jul 07, 2025 |